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Abstract
Background: Plan to illustrate how to care for patients with
Acute Leukemia, with a history of
Li-Fraumeni Syndrome
from the TP53 mutation. There will be discussion about a
newly diagnosed patient with Leukemia and his journey
dealing with Li Fraumeni Syndrome.
Objective: The goal is to provide the audience with education
about Li-Fraumeni Syndrome. Plan to focus on ordering the
appropriate diagnostic testing and promote strategies that
will aid in the care of Li-Fraumeni patients.
Methods: The case study was conducted on a 25-year-old
male diagnosed with Li-Fraumeni Syndrome and the TP53
Mutation was found upon performance of diagnostic testing.
The plan is to further demonstrate how the patient was
diagnosed with Leukemia and what measures that are being
taken to care for him and eventually put the patient into
remission.
Results: Li-Fraumeni Syndrome affects 1 in 5000 live births
worldwide. These patients have a high probability of
developing a wide spectrum of childhood and adult
malignancies. This can result in 50% risk of cancer by age 30
and 80% risk of cancer by age 70.
Conclusion: The outcome is to help readers understand how
patients diagnosed with Li-Fraumeni Syndrome with TP53
mutation are at higher risk of developing cancers such as:
Sarcoma, Adrenocortical, Breast, and Brain cancer. Patients
with Li Fraumeni Syndrome should undergo physical
examination every 6-12 months including whole body and
brain MRI, dermatology and neurological evaluations. These
patient should be monitored closely..
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What is Li-Fraumeni?

Clinical Information

Autosomal dominant disorder linked the germline
mutation in the tumor suppressor gene TP53.
TP53 germline mutation loss of heterozygosity in cancer
cells, resulting in no expressional functional TP53 and is
the presumed mechanism of transformation from
normal to malignant cells.

The cl assical LFS malignancies - sarcoma, cancers of
the breast, brain, and adrenal glands - comprise
a bout 80% of a ll ca ncers that occur i n this
s yndrome.
The ri sk of developing a ny i nvasive cancer
(excl uding skin cancer) is about 50% by a ge 30 (1%
High lifetime probability of developing a wide spectrum
of childhood and adult-onset malignancies
i n the general population) and is 90% by a ge 70.
Ea rl y-onset breast ca ncer a ccounts for 25% of all
50% risk of cancer by age 30
the ca ncers in this syndrome. This is followed by
Core cancer types (SABB)
80% risk of cancer by age 70
s oft-tissue sarcomas (20%), bone sarcoma (15%),
Sarcoma,
Estimated that LFS accounts for 1% of hereditary Breast Adrenal
a nd brain tumors - especially gl ioblastoma- (13%).
cancer.
Breast Brain
Other tumors s een in this s yndrome
Incidence estimated to be 1in 5000 live births
Autosomal Dominate transmission
i ncl ude leukemia, l ymphoma and adrenocortical
worldwide.
Mutations in TP53 gene located ton chromosome 71 ca rci noma
Historical perspective: It was named after two American

•
•

60%-80% of families with classis LFS have a
physicians, Frederick Pei Li and joseph F. Fraumeni, Jr, detectable
who first recognized the syndrome after reviewing the mutation. Stongly condsider TP53 gene testing in
f
medical records and death of 648 childhood
women with Breast cancer.
Rhabdomysarcoma patients. The syndrome is linked to Screening guidelines for patients
germline mutations of the TP 53 tumor suppressor gene. Consider Ultrasound of abdomen & Pelvis in children
If a patient has this gene mutation they are at a higher quarterly
risk of developing Sarcoma, Breast Cancer, Leukemia andBlood test quarterly; CBC, LDH, SED
Adrenal Gland Syndrome.
Annual MRI/ whole body MRI
Leukemia or Lymphoma, consider blood test every 46 months, CBC, ESR, LDH
Colonoscopy and Endoscopy Every 2 years
Annual Dermatology examinations
Breast examinations/mammograms 6mts/yearly

Case Study

Patient P.F.25-year-old male with
history of Li Fraumeni Syndrome/
acuteTP53 mutated leukemia.
Treatment frontline CLIA+ Mylotarg on
protocol Allogenic SCT at MDACC, 4
months post transplant MRD is
undectable and on maintenance
therapy.
ROS; negative
Al l ergies; Allopurinol
PMH; Anxi ety & Depression
Fa mily Hi story: patient adopted
Phys i cal Examination; s table, AAo x3, Lungs;
CTA, Hea rt: RRR,
ABD; s oft nontender
Ski n, no ra shes, Neuro: grossly i ntact
Pa thology; 1/28/22 BMBx Hypocellular (5-10%)
Ma l e with TP53, Mutated Biphentoypic, i n the
s etting of Li -Fraumeni Syndrome. . Pa tient is at
a n i ncreased lifetime risk to develop several
.Ski n biopsy confirmed TP53 pathogenic s plice
va ri a nt,

W h at is Autosomal Dominant?

Recommendations and Management

Autosomal dominant inheritance is a way a genetic trait or condition can be passed down from parent to child. One copy of a
mutated (changed) gene from one parent can cause the genetic condition. A child who has a parent with the mutated gene
has a 50% chance of inheriting that mutated gene.

Management of Li Fraumeni
Genetic counseling and genetic testing are used to confirm that this person has this gene mutation. Once identified with Li-Fraumeni, early
and regular screening for cancer are recommended. The patient with
Li-Fraumeni are likely to develop another primary malignancy in the future 57% within 30 years of diagnosis.
Plan: Lead Clinic referral for surveillance which includes biannual clinic visits with Whole body MRI and Brian MRI, GI Evaluation- EGD and
Colonoscopy every 2-5 years, neurology exam and annual dermatology appointment. Plan to continue to follow up with the patient in clinic
ever 6-12 months.

Management of Li Fraumeni
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